PDE2 Inhibitor Triazolopyrimidines for Potency and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent and well-tolerated phosphodiesterase 2 (PDE2) inhibitors with desirable pharmaceutical properties such as potency, exposure, and selectivity to treat neurological disorders, psychotic disorders, dementia, and other conditions involving PDE2 activity.
Innovation Solution
Development of substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds that act as potent PDE2 inhibitors, including various derivatives and pharmaceutical compositions for administering these compounds to treat related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PDE2 inhibitors are used, then PDE2 inhibition activity is achieved, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical parameters of the triazolo[1,5-a]pyrimidine core structure, including substituting R1 with various heteroaromatic groups (pyridine, pyrimidine, triazine, imidazole, oxazole, thiazole, furan, indole, benzofuran, benzothiophene, dibenzofuran, dibenzothiophene) and adjusting substituents at positions R2, R3, and R4. These structural parameter modifications optimize the compound's binding affinity to PDE2 while enhancing selectivity over other PDE subtypes, achieving both high potency and precise inhibition specificity.
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and substituents at particular positions of the molecular structure. The triazolo[1,5-a]pyrimidine core maintains a consistent scaffold, while local modifications at R1 (heteroaromatic groups), R2 (aryl or heteraryl groups), R3 (electron-withdrawing groups like cyano or carbonyl), and R4 (alkyl or heteraryl groups) create localized chemical properties that optimize PDE2 interaction. This localized structural optimization enables high potency at the active site while maintaining overall molecular integrity.
2Reliability
If PDE2 inhibitors are developed to treat neurological disorders, then therapeutic efficacy is improved, but side effects increase
Solution Approach 1:
The patent applies parameter changes by optimizing the pharmacological parameters of the compound through structural modifications. The electron-withdrawing groups at R3 and electron-donating or neutral groups at R4 are carefully selected to fine-tune the compound's binding affinity and pharmacokinetic properties. This parameter optimization achieves high therapeutic efficacy in neurological disorders while minimizing off-target effects and adverse reactions, creating a favorable safety profile.
Solution Approach 2:
The patent applies this principle by designing compounds with optimized half-lives and clearance characteristics. The triazolo[1,5-a]pyrimidine derivatives are formulated to achieve adequate exposure and efficacy while maintaining acceptable safety margins. The compound pharmacokinetics are optimized to provide sufficient duration of action for therapeutic effect while avoiding accumulation that would cause prolonged side effects.
3Reliability
If compound exposure is increased to improve efficacy, then therapeutic effect is enhanced, but safety profile deteriorates
Solution Approach 1:
The patent applies parameter changes by optimizing the pharmacokinetic parameters of the triazolo[1,5-a]pyrimidine derivatives. The molecular weight, lipophilicity, and metabolic stability are tuned through structural modifications to achieve optimal exposure levels. The compounds are designed to reach sufficient brain penetration and target engagement while maintaining acceptable safety margins, allowing therapeutic efficacy to be achieved at doses that do not produce unacceptable adverse effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit PDE2 activity, enhancing neuronal plasticity, treating neurological disorders, cognitive disorders, and providing neuroprotection, while having a favorable side effect profile.
Implementation Method 1
PDE2 inhibitors have been shown to enhance long term potentiation of synaptic transmission and to improve memory acquisition and consolidation in the object recognition and in the social recognition tests in rats
Data Source
AI summary
The invention provides a chemical entity of Formula (I):wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.